Despite advancements in treating pancreatic ductal adenocarcinoma(PDAC),it remains the third leading cause of cancer-related deaths worldwide and is projected to become the second leading cause within the next decade(...Despite advancements in treating pancreatic ductal adenocarcinoma(PDAC),it remains the third leading cause of cancer-related deaths worldwide and is projected to become the second leading cause within the next decade(1).The 5-year overall survival(OS)rate remains low at just 12%(2),prompting significant efforts to develop new multimodal therapies.While adjuvant therapy has been shown to improve OS after pancreatic cancer resection,many patients are unable to receive it either because of major postoperative complications,poor functional status after surgery,or early cancer recurrence(3,4).Subsequently,the use of chemotherapy and/or chemoradiation therapy prior to surgery,known as neoadjuvant therapy(NT),has significantly increased in the United States and around the world over the past several decades(5).In addition to improving the delivery of multimodality therapy,this approach may also facilitate downstaging of borderline resectable(BR)or locally advanced(LA)cancers and increases the likelihood of a margin-negative resection.展开更多
文摘Despite advancements in treating pancreatic ductal adenocarcinoma(PDAC),it remains the third leading cause of cancer-related deaths worldwide and is projected to become the second leading cause within the next decade(1).The 5-year overall survival(OS)rate remains low at just 12%(2),prompting significant efforts to develop new multimodal therapies.While adjuvant therapy has been shown to improve OS after pancreatic cancer resection,many patients are unable to receive it either because of major postoperative complications,poor functional status after surgery,or early cancer recurrence(3,4).Subsequently,the use of chemotherapy and/or chemoradiation therapy prior to surgery,known as neoadjuvant therapy(NT),has significantly increased in the United States and around the world over the past several decades(5).In addition to improving the delivery of multimodality therapy,this approach may also facilitate downstaging of borderline resectable(BR)or locally advanced(LA)cancers and increases the likelihood of a margin-negative resection.
